aVenture is in Alpha: aVenture recently launched early public access to our research product. It's intended to illustrate capabilities and gather feedback from users. While in Alpha, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to temporarily present this information to showcase the product's potential, but you should not yet rely upon it for your investment decisions.
aVenture is in Alpha: aVenture recently launched early public access to our research product. It's intended to illustrate capabilities and gather feedback from users. While in Alpha, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to temporarily present this information to showcase the product's potential, but you should not yet rely upon it for your investment decisions.
© aVenture Investment Company, 2024. All rights reserved.
44 Tehama St, San Francisco, CA 94105
Privacy Policy
aVenture Investment Company ("aVenture") is an independent venture capital research platform providing detailed analysis and data on startups, venture capital investments, and key industry individuals.
While we strive to provide valuable insights with objectivity and professional diligence, we cannot guarantee the accuracy of the information provided on our platform. Before making any investment decisions, you should verify the accuracy of all pertinent details for your decision.
aVenture does not offer investment advisory services and is not registered as an investment adviser. The data provided by aVenture does not constitute recommendations or advice, whether by methodology or a statement written by a staff member of aVenture.
Links to external websites do not imply endorsement or affiliation with aVenture. References or links to providers offering the ability to invest in a primary or secondary transaction in a company are for convenience purposes only. They are not solicitations or offers to buy or sell an investment. Remember that past performance does not guarantee future results, and venture capital and private assets should be a contributory part of a diversified portfolio.
Ochre Bio: Biotech firm creating RNA meds & platforms for liver health.
Ochre Bio, founded with a mission to revolutionize liver health, focuses on developing RNA medicines to treat chronic liver diseases. The company aims to leverage advanced biotechnology to create innovative therapeutic solutions that address unmet medical needs in hepatology. By combining cutting-edge RNA technology with a deep understanding of liver biology, Ochre Bio is dedicated to improving patient outcomes and advancing the field of liver disease treatment.
Notable figures associated with Ochre Bio include Sangeeta Bhatia, a member of the Scientific Advisory Board, and Ness Bermingham, a board member. The company has made significant strides in its research and development efforts, positioning itself as a leader in the biotech space focused on liver health. Through its pioneering work in RNA medicine, Ochre Bio has the potential to make a substantial impact on the treatment landscape for chronic liver conditions, offering hope to millions of patients worldwide.
Operating Status
Active
Ownership Type(s)
Venture Capital
Main Product(s)
RNA Medicines
Technology
Biotech
Tags
Healthtech
Revenue Type(s)
Recurring
Customer Type(s)
Enterprise
Geographic Exposure
Global
When was Ochre Bio founded?
Ochre Bio was founded in 2019.
Where is Ochre Bio’s headquarters located?
Ochre Bio’s headquarters is located in Oxford, GB.
When was Ochre Bio’s last funding round?
Ochre Bio’s most recent funding round was for $30M (USD) in October 2022.
How many employees does Ochre Bio have?
Ochre Bio has 56 employees as of Feb 24, 2024.
How much has Ochre Bio raised to-date?
As of July 05, 2023, Ochre Bio has raised a total of $39.8M (USD) since Oct 10, 2022.
Add Comparison
Total Raised to Date
$39.8M
USD
Last Update Oct 10, 2022
Last Deal Details
$30M
USD
Oct 10, 2022
Series A
Total Employees Over Time
56
As of Feb 2024
Ochre Bio Address
Oxford,
United Kingdom
Source(s): This page includes data and analysis provided by the company, OpenAI, and our research analysts